Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
172.90
0.00 (0.00%)
Jun 17, 2025, 4:00 PM - Market closed
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 100.95M EUR in the quarter ending March 31, 2025, with 5.28% growth. This brings the company's revenue in the last twelve months to 368.70M, up 12.06% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
368.70M EUR
Revenue Growth
+12.06%
P/S Ratio
25.46
Revenue / Employee
362,538 EUR
Employees
1,017
Market Cap
10.44B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ASND News
- 8 days ago - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial - GlobeNewsWire
- 15 days ago - FDA Accepts TransCon® CNP NDA for Priority Review - GlobeNewsWire
- 4 weeks ago - Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction - Accesswire
- 5 weeks ago - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) - GlobeNewsWire
- 5 weeks ago - New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism - GlobeNewsWire
- 6 weeks ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewsWire